{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:31:57Z","timestamp":1778697117633,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.breast.2020.09.011","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T05:47:54Z","timestamp":1601444874000},"page":"256-263","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study"],"prefix":"10.1016","volume":"54","author":[{"given":"Anne-Claire","family":"Hardy-Bessard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabien","family":"Brocard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Clatot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Lortholary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beno\u00eet","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Grenier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Martin-Babau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Meunier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude-Marie","family":"Savoye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adina","family":"Marti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Despax","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Moullet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8505-4387","authenticated-orcid":false,"given":"George","family":"Emile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2020.09.011_bib1","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2020.09.011_bib2","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.09.011_bib3","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.09.011_bib4","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2016.09.024","article-title":"Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): a double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation","volume":"70","author":"Miles","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.breast.2020.09.011_bib5","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1080\/03007995.2019.1595551","article-title":"Treatment patterns, health care resource use and outcomes in metastatic triple-negative breast cancer in Germany: retrospective chart review study (OBTAIN)","volume":"31","author":"Schilling","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.breast.2020.09.011_bib6","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"key":"10.1016\/j.breast.2020.09.011_bib7","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1158\/0008-5472.CAN-17-1467","article-title":"Peripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery","volume":"78","author":"Wozniak","year":"2018","journal-title":"Canc Res"},{"key":"10.1016\/j.breast.2020.09.011_bib8","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s10549-010-1278-0","article-title":"Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy","volume":"125","author":"Hershman","year":"2011","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2020.09.011_bib9","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1517\/14740338.2015.1056777","article-title":"Minimizing chemotherapy-induced peripheral neuropathy: preclinical and clinical development of new perspectives","volume":"14","author":"Poupon","year":"2015","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.breast.2020.09.011_bib10","author":"Registration GmbH"},{"key":"10.1016\/j.breast.2020.09.011_bib11","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1007\/s13277-014-2799-7","article-title":"The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials","volume":"36","author":"Fang","year":"2015","journal-title":"Tumour Biol"},{"key":"10.1016\/j.breast.2020.09.011_bib12","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1038\/bjc.2016.326","article-title":"Genotypes of CYP2C8 and FGD4 and their association with peripheral neuropathy or early dose reduction in paclitaxel-treated breast cancer patients","volume":"115","author":"Lam","year":"2016","journal-title":"Br J Canc"},{"key":"10.1016\/j.breast.2020.09.011_bib13","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S1470-2045(16)30154-1","article-title":"TURANDOT investigators. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial","volume":"17","author":"Zielinski","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2020.09.011_bib14","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1200\/JCO.2014.59.5298","volume":"33","author":"Rugo","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.09.011_bib15","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician\u2019s Choice versus E7389) investigators. Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2020.09.011_bib16","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1200\/JCO.2013.52.4892","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.09.011_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2019.02.002","article-title":"Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: a randomised clinical trial","volume":"112","author":"Yuan","year":"2019","journal-title":"Eur J Canc"},{"key":"10.1016\/j.breast.2020.09.011_bib18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10549-014-2923-9","article-title":"Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer","volume":"146","author":"McIntyre","year":"2014","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2020.09.011_bib19","first-page":"105","article-title":"Phase II, multicenter, single-arm trial of eribulin as first-line therapy for patients with aggressive taxane-pretreated HER2-negative metastatic breast cancer: the MERIBEL study","volume":"19","author":"Ortega","year":"2019","journal-title":"Clin Breast Canc"},{"key":"10.1016\/j.breast.2020.09.011_bib20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s40064-016-1833-1","article-title":"A\u00a0phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer","volume":"5","author":"Takashima","year":"2016","journal-title":"Springerplus"},{"key":"10.1016\/j.breast.2020.09.011_bib21","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1158\/0008-5472.CAN-10-4184","article-title":"Comparison of neuropathy-inducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice","volume":"71","author":"Wozniak","year":"2011","journal-title":"Canc Res"},{"key":"10.1016\/j.breast.2020.09.011_bib22","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s12640-017-9729-6","article-title":"Microtubule-targeting agents eribulin and paclitaxel differentially affect neuronal cell bodies in chemotherapy-induced peripheral neuropathy","volume":"32","author":"Benbow","year":"2017","journal-title":"Neurotox Res"},{"key":"10.1016\/j.breast.2020.09.011_bib23","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s12640-013-9394-3","article-title":"Neuropathy-inducing effects of eribulin mesylate versus paclitaxel in mice with preexisting neuropathy","volume":"24","author":"Wozniak","year":"2013","journal-title":"Neurotox Res"},{"key":"10.1016\/j.breast.2020.09.011_bib24","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejca.2016.03.010","article-title":"Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial","volume":"60","author":"Aftimos","year":"2016","journal-title":"Eur J Canc"},{"key":"10.1016\/j.breast.2020.09.011_bib25","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1186\/s12885-015-1673-3","article-title":"Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study","volume":"15","author":"Dell\u2019Ova","year":"2015","journal-title":"BMC Canc"},{"key":"10.1016\/j.breast.2020.09.011_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s12282-018-0919-8","article-title":"Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study","volume":"26","author":"Tsurutani","year":"2019","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2020.09.011_bib27","doi-asserted-by":"crossref","first-page":"112076","DOI":"10.18632\/oncotarget.21057","article-title":"Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis","volume":"8","author":"Peng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.breast.2020.09.011_bib28","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.21873\/anticanres.12604","article-title":"Broad-spectrum preclinical antitumor activity of eribulin (Halaven\u00ae): combination with anticancer agents of differing mechanisms","volume":"38","author":"Asano","year":"2018","journal-title":"Anticancer Res"},{"key":"10.1016\/j.breast.2020.09.011_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials control","volume":"10","author":"Simon","year":"1989","journal-title":"Clin Trials"},{"key":"10.1016\/j.breast.2020.09.011_bib30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejca.2017.10.002","article-title":"Korean Cancer Study Group (KCSG). Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer","volume":"86","author":"Park","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.breast.2020.09.011_bib31","first-page":"29","volume":"39","author":"Kim","year":"2019","journal-title":"Canc Commun"},{"key":"10.1016\/j.breast.2020.09.011_bib32","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/S1470-2045(14)70444-9","article-title":"Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial","volume":"15","author":"Gligorov","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2020.09.011_bib33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1186\/s12885-018-4556-6","volume":"18","author":"Inoue","year":"2018","journal-title":"BMC Canc"},{"key":"10.1016\/j.breast.2020.09.011_bib34","first-page":"471","article-title":"Ramucirumab with eribulin versus eribulin in locally recurrent or metastatic breast cancer previously treated with anthracycline and taxane therapy: a multicenter, randomized, phase II study","volume":"16","author":"Yardley","year":"2016","journal-title":"Clin Breast Canc"},{"key":"10.1016\/j.breast.2020.09.011_bib35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.2014.57.1513","article-title":"Primary results of ROSE\/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer","volume":"33","author":"Mackey","year":"2015","journal-title":"J\u00a0Clin Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977620301892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977620301892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:43:48Z","timestamp":1760777028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977620301892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":35,"alternative-id":["S0960977620301892"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2020.09.011","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2020.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}